Search
-
[WEBINAR] How GLP-1 drugs change the game for food and beverage, retail, travel and beyond
From aviation to government to retail, including food and beverage, restaurants, cosmetics and skincare, and of course, healthcare, there are a wide range of sectors that could be impacted by GLP-1 usage.
-
Food
Obesity drugs, private-label foods and shifting social patterns are disrupting America’s food landscape. What the Future lays out how food makers to packaging companies to appliance makers can thrive in these changes.
-
How obesity drugs, politics and climate change are shaping the future of food
In the six years since our first Food issue, several of What the Future’s future scenarios have come to fruition. Editor Matt Carmichael looks at those shifts and others that will shape the decade to come, from obesity medications to politicization.
-
Shifts: Personalized nutrition, food politics and regenerative architecture
Ipsos Strategy3’s Trevor Sudano sets the table for the issue with a look at three key forces reshaping Americans’ food and drink habits: personalization, politicization and sustainability.
-
How institutions and policy can lead to healthier, more sustainable food
Kate MacKenzie, director of the New York City Mayor’s Office of Food Policy, explains what it takes to feed 1 million school children at scale — and how institutions can influence healthier eating for people and the planet.
-
How food companies can meet diners’ needs everywhere
Ipsos’ Anne Hunter explains how food manufacturers can maximize sales in every environment by understanding the distinct needs of consumers and professional food buyers.
-
Why diverse approaches and collaboration are vital for future protein needs
As demand for protein expands, brands will need to innovate quickly and strategically to meet these needs without overly relying on any one innovation, says Cargill’s Florian Schattenmann.
-
How social listening can inform better research and development
New AI tools can help brands keep up with fast-moving social conversations to spot industry signals and trends to steer smarter innovation, says Ipsos’ Joe Lonek.
-
Why GLP-1 drugs’ impact on food will be more evolution than revolution
GLP-1s could revolutionize Americans’ diets, but brands and businesses need to consider these treatments in context, according to Erin Lash, director of consumer sector equity research for Morningstar.
-
How brands can get more context about the impact of weight-loss drugs
GLP-1s have the potential to transform not just Americans’ diets, but their broader lifestyles and cross-category consumption habits. To get the complete picture, brands need human-centric research, says Ipsos’ Alexandra Stiver.